Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

IMPORTANCE: Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this combination’s tolerability and impact on minimal residual disease (MRD) negativity because this end point has be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Korde, Neha, Roschewski, Mark, Zingone, Adriana, Kwok, Mary, Manasanch, Elisabet E., Bhutani, Manisha, Tageja, Nishant, Kazandjian, Dickran, Mailankody, Sham, Wu, Peter, Morrison, Candis, Costello, Rene, Zhang, Yong, Burton, Debra, Mulquin, Marcia, Zuchlinski, Diamond, Lamping, Liz, Carpenter, Ashley, Wall, Yvonne, Carter, George, Cunningham, Schuyler C., Gounden, Verena, Sissung, Tristan M., Peer, Cody, Maric, Irina, Calvo, Katherine R., Braylan, Raul, Yuan, Constance, Stetler-Stevenson, Maryalice, Arthur, Diane C., Kong, Katherine A., Weng, Li, Faham, Malek, Lindenberg, Liza, Kurdziel, Karen, Choyke, Peter, Steinberg, Seth M., Figg, William, Landgren, Ola
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6662597/
https://ncbi.nlm.nih.gov/pubmed/26181891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.2010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados